B-type natriuretic peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants

Korean Circulation Journal

Volumn 42, Issue 3, 2012, Pages 192-196

  Kim, Joon Sik ^a   Shim, Eun Jung ^a  

^a Hallym University   (South Korea)

Author keywords

B type natriuretic peptide; Echocardiography; Patent ductus arteriosus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84859886155     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2012.42.3.192     Document Type: Article

References (30)

1. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88:192-201. (Pubitemid 41433551)
2. Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol 1987;11:64-71.
3. Heymann MA, Rudolf AM. Control of the ductus arteriosus. Physiol Rev 1975;55:62-78.
4. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006;89:330-5. (Pubitemid 43886949)
5. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126:605-10.
6. Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000;137:68-72. (Pubitemid 30470925)
7. Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 1995;22:457-79.
8. Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978;92:467-73. (Pubitemid 8296513)
9. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992;90:899-904.
10. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42. (Pubitemid 40981143)
11. Holmström H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001;90:184-91. (Pubitemid 32222804)
12. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68. (Pubitemid 50011582)
13. Cantinotti M, Clerico A, Murzi M, Vittorini S, Emdin M. Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. Clin Chim Acta 2008;390:12-22.
14. Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-304. Erratum in: Pediatrics 2005;115:1454. (Pubitemid 41647692)
15. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002;103:75-7. (Pubitemid 34729127)
16. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009;94:F178-82.
17. Evans N. Diagnosis of patent ductus arteriosus in the preterm newborn. Arch Dis Child 1993;68(1 Spec No):58-61.
18. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echochardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994;30:406-11. (Pubitemid 24304038)
19. Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001;6:49-61. (Pubitemid 32127003)
20. Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 1999;134:552-7. (Pubitemid 30180592)
21. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005;F90:419-22.
22. Young TE, Mangum B. Neofax: a Manual of Drugs Used in Neonatal Care. 20th ed. Montvale, NJ: Thompson Healthcare; 2007.
23. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8. (Pubitemid 28366422)
24. Da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006;117;2183-9. (Pubitemid 46071264)
25. Lee HS, Choi WS, Choi BM, et al. Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants. J Korean Soc Neonatol 2004;11:44-53.
26. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61.
27. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010;157:79-84.
28. Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-59. (Pubitemid 35222850)
29. Ueda S, Nishio K, Akai Y, et al. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006;26:134-9. (Pubitemid 44162498)
30. El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed 2007;92:F320-4. (Pubitemid 47013007)